person · Reporting owner

Lucera Erick

Disclosed activity across 7 companies

Tapewire entity: 22905
SEC CIK: 0001697616

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Beyond Air, Inc.XAIR · Entity 8379	Director	November 04, 2025	November 07, 2025
Bone Biologics CorpBBLG · Entity 8560	Director	September 18, 2023	September 20, 2023
Dyne Therapeutics, Inc.DYN · Entity 3948	Chief Financial Officer	August 13, 2026	August 17, 2026
SAB Biotherapeutics, Inc.SABS · Entity 5816	Director	December 16, 2025	December 18, 2025
Valeritas Holdings Inc.VLRX · Entity 152233	See Remarks	March 07, 2019	March 08, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Beyond Air, Inc.

Report date November 04, 2025 · Filed November 07, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.80	Direct	0	Reported balance After 2025-11-04 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-11-04 · Disposition to issuer · Disposed 2,250 · Balance 0 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95	Direct	2,250	Reported balance After 2025-11-04 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-11-04 · Grant · Acquired 2,250 · Balance 2,250 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.80	Direct	0	Reported balance After 2025-11-04 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-11-04 · Disposition to issuer · Disposed 2,000 · Balance 0 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95	Direct	2,000	Reported balance After 2025-11-04 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-11-04 · Grant · Acquired 2,000 · Balance 2,000 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.80	Direct	0	Reported balance After 2025-11-04 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-11-04 · Disposition to issuer · Disposed 1,500 · Balance 0 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95	Direct	1,500	Reported balance After 2025-11-04 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2025-11-04 · Grant · Acquired 1,500 · Balance 1,500 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.80	Direct	0	Reported balance After 2025-11-04 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2025-11-04 · Disposition to issuer · Disposed 1,250 · Balance 0 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95	Direct	1,250	Reported balance After 2025-11-04 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2025-11-04 · Grant · Acquired 1,250 · Balance 1,250 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.80	Direct	0	Reported balance After 2025-11-04 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2025-11-04 · Disposition to issuer · Disposed 1,250 · Balance 0 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95	Direct	1,250	Reported balance After 2025-11-04 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2025-11-04 · Grant · Acquired 1,250 · Balance 1,250 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.80	Direct	0	Reported balance After 2025-11-04 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2025-11-04 · Disposition to issuer · Disposed 1,000 · Balance 0 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95	Direct	1,000	Reported balance After 2025-11-04 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2025-11-04 · Grant · Acquired 1,000 · Balance 1,000 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.80	Direct	0	Reported balance After 2025-11-04 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2025-11-04 · Disposition to issuer · Disposed 1,250 · Balance 0 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95	Direct	1,250	Reported balance After 2025-11-04 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2025-11-04 · Grant · Acquired 1,250 · Balance 1,250 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.89	Direct	0	Reported balance After 2025-11-04 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2025-11-04 · Disposition to issuer · Disposed 3,750 · Balance 0 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95	Direct	3,750	Reported balance After 2025-11-04 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2025-11-04 · Grant · Acquired 3,750 · Balance 3,750 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged.

F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

Bone Biologics Corp

Report date September 18, 2023 · Filed September 20, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.64 · Expires 2033-09-13	Direct	85,763	Reported balance After 2023-09-18 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-09-18 · Grant · Acquired 85,763 · Balance 85,763 F1: Vests quarterly through the date of the next annual meeting of the stockholders of the Company following the Grant.
Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $48.41 · Expires 2027-08-23	Direct	1,229	Reported balance Holding disclosure · report date 2023-09-18 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance 1,229 F2: This option is fully vested as of the date of this report.
Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $105.60 · Expires 2032-01-01	Direct	291	Reported balance Holding disclosure · report date 2023-09-18 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance 291 F2: This option is fully vested as of the date of this report.
Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $157.50 · Expires 2031-10-26	Direct	99	Reported balance Holding disclosure · report date 2023-09-18 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance 99 F2: This option is fully vested as of the date of this report.
Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $157.50 · Expires 2031-10-15	Direct	677	Reported balance Holding disclosure · report date 2023-09-18 · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · Balance 677 F2: This option is fully vested as of the date of this report.

Filing footnotes · ownership attribution and instrument terms

F1: Vests quarterly through the date of the next annual meeting of the stockholders of the Company following the Grant.

F2: This option is fully vested as of the date of this report.

Dyne Therapeutics, Inc.

Report date August 13, 2026 · Filed August 17, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	119,766	Reported balance After 2026-08-13 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-08-13 · Sale · Disposed 1,797 · Balance 119,766 F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on February 12, 2026. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.17 to $26.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3: Includes 106,451 unvested RSUs.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on February 12, 2026. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.17 to $26.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.

F3: Includes 106,451 unvested RSUs.

SAB Biotherapeutics, Inc.

Report date December 16, 2025 · Filed December 18, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.99 · Expires 2035-12-16	Direct	150,000	Reported balance After 2025-12-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-12-16 · Grant · Acquired 150,000 · Balance 150,000 F1: Represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on December 16, 2026 and December 16, 2027. F2: This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on December 16, 2026 and December 16, 2027.

F2: This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

Valeritas Holdings Inc.

Report date March 07, 2019 · Filed March 08, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.43 · Expires 2029-03-07	Direct	280,000	Reported balance After 2019-03-07 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-03-07 · Grant · Acquired 280,000 · Balance 280,000 F1: 25% of the option shall vest on March 07, 2020, the one-year anniversary of the date of grant. The remaining shares underlying the option vest in substantially equal quarterly installments for 8 quarters after such one-year anniversary, such that the option will fully vest on March 07, 2022.

Filing footnotes · ownership attribution and instrument terms

F1: 25% of the option shall vest on March 07, 2020, the one-year anniversary of the date of grant. The remaining shares underlying the option vest in substantially equal quarterly installments for 8 quarters after such one-year anniversary, such that the option will fully vest on March 07, 2022.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

AVEO PHARMACEUTICALS, INC.

Report date January 19, 2023 · Filed January 19, 2023

Section 16 reporting ended · disclosed 2023-01-19. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.70 · Expires 2030-01-05	Direct	Reported balance After 2023-01-19 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-01-19 · Disposition to issuer · Disposed 50,000 · Balance 0 F1: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.12 · Expires 2031-02-05	Direct	Reported balance After 2023-01-19 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-01-19 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.67 · Expires 2032-02-15	Direct	Reported balance After 2023-01-19 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-01-19 · Disposition to issuer · Disposed 218,800 · Balance 0 F1: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes.

Editas Medicine, Inc.

Report date March 08, 2025 · Filed March 27, 2025

Section 16 reporting ended · disclosed 2025-03-27. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.72 · Expires 2035-03-07	Direct	275,100	Reported balance After 2025-03-08 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-03-08 · Grant · Acquired 275,100 · Balance 275,100 F1: This option was granted on March 8, 2025 and is scheduled to vest over four years in equal monthly installments beginning on April 8, 2025 through March 8, 2029.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.72 · Expires 2035-03-07	Direct	70,000	Reported balance After 2025-03-08 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-03-08 · Grant · Acquired 70,000 · Balance 70,000 F2: This option was granted on March 8, 2025 and is scheduled to vest in full on September 8, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: This option was granted on March 8, 2025 and is scheduled to vest over four years in equal monthly installments beginning on April 8, 2025 through March 8, 2029.

F2: This option was granted on March 8, 2025 and is scheduled to vest in full on September 8, 2026.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 13, 2026 Filed Aug 17, 2026 20:06 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	SaleCommon Stock	1,797	$26.28	$47,225.16	Disclosure SEC source: 0001697616-26-000002 · ownership.xml · nonDerivative · entry 1 Lucera Erick · CIK 0001697616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,766 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on February 12, 2026. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.17 to $26.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 106,451 unvested RSUs. Read SEC document
June 25, 2026 Filed Jun 26, 2026 20:15 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	SaleCommon Stock	2,362	$20.37	$48,113.94	Disclosure SEC source: 0001193125-26-285505 · ownership.xml · nonDerivative · entry 1 Lucera Erick · CIK 0001697616 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,563 F1 · kind: Represents shares sold to satisfy certain tax obligations of the Reporting Person incurred with the vesting and settlement of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.33 to $20.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 110,513 unvested RSUs. Read SEC document
May 13, 2026 Filed May 14, 2026 20:03 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	SaleCommon Stock	1,448	$18.36	$26,585.28	Disclosure SEC source: 0001193125-26-223961 · ownership.xml · nonDerivative · entry 1 Lucera Erick · CIK 0001697616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,925 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on February 12, 2026. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.20 to $18.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 110,513 unvested RSUs. Read SEC document
April 01, 2026 Filed Apr 3, 2026 20:10 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	SaleCommon Stock	5,727	$18.64	$106,751.28	Disclosure SEC source: 0001193125-26-142137 · ownership.xml · nonDerivative · entry 1 Lucera Erick · CIK 0001697616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,373 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on March 31, 2025. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.24 to $18.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 114,575 unvested RSUs. Read SEC document
February 12, 2026 Filed Feb 17, 2026 22:08 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	GrantStock Option (Right to Buy) · Derivative	105,000	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0001193125-26-055052 · ownership.xml · derivative · entry 2 Lucera Erick · CIK 0001697616 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2036-02-11 F3 · derivative.exercise_date: This option was granted on February 12, 2026. The shares underlying the option are scheduled to vest over four years in equal monthly installments through February 12, 2030. Read SEC document
February 12, 2026 Filed Feb 17, 2026 22:08 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	GrantCommon Stock	65,000	$0.00	$0.00	Disclosure SEC source: 0001193125-26-055052 · ownership.xml · nonDerivative · entry 1 Lucera Erick · CIK 0001697616 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,100 F1 · shares: Consists of shares of Common Stock issuable under 65,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on May 12, 2026. F2 · balance_after: Includes 131,100 unvested RSUs. Read SEC document
December 16, 2025 Filed Dec 18, 2025 21:50 UTC	SAB Biotherapeutics, Inc. SABS · Entity 5816	GrantStock option (right to buy) · Derivative	150,000	$0.00 Strike: $3.99	$0.00	Disclosure SEC source: 0001193125-25-324991 · ownership.xml · derivative · entry 1 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2035-12-16 F1 · security: Represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on December 16, 2026 and December 16, 2027. F2 · security: This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended. F1 · derivative.exercise_date: Represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on December 16, 2026 and December 16, 2027. Read SEC document
November 04, 2025 Filed Nov 7, 2025 02:51 UTC	Beyond Air, Inc. XAIR · Entity 8379	GrantStock Options (Right to buy) · Derivative	3,750	Not disclosed Strike: $1.95	Not disclosed	Disclosure SEC source: 0001493152-25-021154 · ownership.xml · derivative · entry 16 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires not disclosed F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F1 · price: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
November 04, 2025 Filed Nov 7, 2025 02:51 UTC	Beyond Air, Inc. XAIR · Entity 8379	Disposition to issuerStock Options (Right to buy) · Derivative	3,750	Not disclosed Strike: $5.89	Not disclosed	Disclosure SEC source: 0001493152-25-021154 · ownership.xml · derivative · entry 15 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,750 shares Expires not disclosed F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F1 · price: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
November 04, 2025 Filed Nov 7, 2025 02:51 UTC	Beyond Air, Inc. XAIR · Entity 8379	GrantStock Options (Right to buy) · Derivative	1,250	Not disclosed Strike: $1.95	Not disclosed	Disclosure SEC source: 0001493152-25-021154 · ownership.xml · derivative · entry 14 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,250 Underlying: Common Stock · 1,250 shares Expires not disclosed F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F1 · price: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
November 04, 2025 Filed Nov 7, 2025 02:51 UTC	Beyond Air, Inc. XAIR · Entity 8379	Disposition to issuerStock Options (Right to buy) · Derivative	1,250	Not disclosed Strike: $10.80	Not disclosed	Disclosure SEC source: 0001493152-25-021154 · ownership.xml · derivative · entry 13 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,250 shares Expires not disclosed F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F1 · price: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
November 04, 2025 Filed Nov 7, 2025 02:51 UTC	Beyond Air, Inc. XAIR · Entity 8379	GrantStock Options (Right to buy) · Derivative	1,000	Not disclosed Strike: $1.95	Not disclosed	Disclosure SEC source: 0001493152-25-021154 · ownership.xml · derivative · entry 12 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 1,000 shares Expires not disclosed F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F1 · price: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
November 04, 2025 Filed Nov 7, 2025 02:51 UTC	Beyond Air, Inc. XAIR · Entity 8379	Disposition to issuerStock Options (Right to buy) · Derivative	1,000	Not disclosed Strike: $10.80	Not disclosed	Disclosure SEC source: 0001493152-25-021154 · ownership.xml · derivative · entry 11 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,000 shares Expires not disclosed F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F1 · price: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
November 04, 2025 Filed Nov 7, 2025 02:51 UTC	Beyond Air, Inc. XAIR · Entity 8379	GrantStock Options (Right to buy) · Derivative	1,250	Not disclosed Strike: $1.95	Not disclosed	Disclosure SEC source: 0001493152-25-021154 · ownership.xml · derivative · entry 10 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,250 Underlying: Common Stock · 1,250 shares Expires not disclosed F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F1 · price: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
November 04, 2025 Filed Nov 7, 2025 02:51 UTC	Beyond Air, Inc. XAIR · Entity 8379	Disposition to issuerStock Options (Right to buy) · Derivative	1,250	Not disclosed Strike: $10.80	Not disclosed	Disclosure SEC source: 0001493152-25-021154 · ownership.xml · derivative · entry 9 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,250 shares Expires not disclosed F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F1 · price: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
November 04, 2025 Filed Nov 7, 2025 02:51 UTC	Beyond Air, Inc. XAIR · Entity 8379	GrantStock Options (Right to buy) · Derivative	1,250	Not disclosed Strike: $1.95	Not disclosed	Disclosure SEC source: 0001493152-25-021154 · ownership.xml · derivative · entry 8 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,250 Underlying: Common Stock · 1,250 shares Expires not disclosed F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F1 · price: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
November 04, 2025 Filed Nov 7, 2025 02:51 UTC	Beyond Air, Inc. XAIR · Entity 8379	Disposition to issuerStock Options (Right to buy) · Derivative	1,250	Not disclosed Strike: $10.80	Not disclosed	Disclosure SEC source: 0001493152-25-021154 · ownership.xml · derivative · entry 7 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,250 shares Expires not disclosed F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F1 · price: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
November 04, 2025 Filed Nov 7, 2025 02:51 UTC	Beyond Air, Inc. XAIR · Entity 8379	GrantStock Options (Right to buy) · Derivative	1,500	Not disclosed Strike: $1.95	Not disclosed	Disclosure SEC source: 0001493152-25-021154 · ownership.xml · derivative · entry 6 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires not disclosed F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F1 · price: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
November 04, 2025 Filed Nov 7, 2025 02:51 UTC	Beyond Air, Inc. XAIR · Entity 8379	Disposition to issuerStock Options (Right to buy) · Derivative	1,500	Not disclosed Strike: $10.80	Not disclosed	Disclosure SEC source: 0001493152-25-021154 · ownership.xml · derivative · entry 5 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires not disclosed F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F1 · price: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
November 04, 2025 Filed Nov 7, 2025 02:51 UTC	Beyond Air, Inc. XAIR · Entity 8379	GrantStock Options (Right to buy) · Derivative	2,000	Not disclosed Strike: $1.95	Not disclosed	Disclosure SEC source: 0001493152-25-021154 · ownership.xml · derivative · entry 4 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires not disclosed F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F1 · price: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
November 04, 2025 Filed Nov 7, 2025 02:51 UTC	Beyond Air, Inc. XAIR · Entity 8379	Disposition to issuerStock Options (Right to buy) · Derivative	2,000	Not disclosed Strike: $10.80	Not disclosed	Disclosure SEC source: 0001493152-25-021154 · ownership.xml · derivative · entry 3 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires not disclosed F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F1 · price: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
November 04, 2025 Filed Nov 7, 2025 02:51 UTC	Beyond Air, Inc. XAIR · Entity 8379	GrantStock Options (Right to buy) · Derivative	2,250	Not disclosed Strike: $1.95	Not disclosed	Disclosure SEC source: 0001493152-25-021154 · ownership.xml · derivative · entry 2 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,250 Underlying: Common Stock · 2,250 shares Expires not disclosed F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F1 · price: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
November 04, 2025 Filed Nov 7, 2025 02:51 UTC	Beyond Air, Inc. XAIR · Entity 8379	Disposition to issuerStock Options (Right to buy) · Derivative	2,250	Not disclosed Strike: $10.80	Not disclosed	Disclosure SEC source: 0001493152-25-021154 · ownership.xml · derivative · entry 1 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,250 shares Expires not disclosed F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F1 · price: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
March 31, 2025 Filed Apr 1, 2025 20:33 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	GrantStock Option (Right to Buy) · Derivative	214,500	$0.00 Strike: $10.46	$0.00	Disclosure SEC source: 0000950170-25-048601 · ownership.xml · derivative · entry 2 Lucera Erick · CIK 0001697616 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 214,500 Underlying: Common Stock · 214,500 shares Expires 2035-03-30 F2 · derivative.exercise_date: The option was granted on March 31, 2025. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 31, 2026, and the remainder vesting in 12 equal quarterly installments thereafter, subject to continuous service. Read SEC document
March 31, 2025 Filed Apr 1, 2025 20:33 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	GrantCommon Stock	66,100	$0.00	$0.00	Disclosure SEC source: 0000950170-25-048601 · ownership.xml · nonDerivative · entry 1 Lucera Erick · CIK 0001697616 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,100 F1 · shares: Consists of shares of Common Stock issuable under 66,100 restricted stock units ("RSU"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest as to 25% of the shares in equal annual installments over four years with the first installment vesting on March 31, 2026, subject to continuous service. Read SEC document
March 26, 2025 Filed Mar 28, 2025 21:12 UTC	Beyond Air, Inc. XAIR · Entity 8379	GrantStock Options (Right to buy) · Derivative	75,000	$0.00 Strike: $0.29	$0.00	Disclosure SEC source: 0001641172-25-001285 · ownership.xml · derivative · entry 1 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2035-03-26 F1 · derivative.exercise_date: The option will vest as to 25% of the shares of common stock underlying the option on December 31, 2025, with the remainder vesting in equal annual installments on December 31 of each of the three ensuing years thereafter until vested in full. Read SEC document
March 08, 2025 Filed Mar 27, 2025 20:41 UTC	Editas Medicine, Inc. EDIT · Entity 5502	GrantStock Option (right to buy) · Derivative	70,000	$0.00 Strike: $1.72	$0.00	Disclosure SEC source: 0001650664-25-000040 · wk-form4_1743108110.xml · derivative · entry 2 Lucera Erick · CIK 0001697616 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2035-03-07 F2 · derivative.exercise_date: This option was granted on March 8, 2025 and is scheduled to vest in full on September 8, 2026. Read SEC document
March 08, 2025 Filed Mar 27, 2025 20:41 UTC	Editas Medicine, Inc. EDIT · Entity 5502	GrantStock Option (right to buy) · Derivative	275,100	$0.00 Strike: $1.72	$0.00	Disclosure SEC source: 0001650664-25-000040 · wk-form4_1743108110.xml · derivative · entry 1 Lucera Erick · CIK 0001697616 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,100 Underlying: Common Stock · 275,100 shares Expires 2035-03-07 F1 · derivative.exercise_date: This option was granted on March 8, 2025 and is scheduled to vest over four years in equal monthly installments beginning on April 8, 2025 through March 8, 2029. Read SEC document
March 04, 2025 Filed Mar 5, 2025 21:44 UTC	Editas Medicine, Inc. EDIT · Entity 5502	SaleCommon Stock	4,109	$1.71	$7,029.68	Disclosure SEC source: 0001650664-25-000027 · wk-form4_1741211041.xml · nonDerivative · entry 1 Lucera Erick · CIK 0001697616 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,720 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on May 12, 2023, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 3, 2025. The sale does not represent a discretionary trade by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $1.7107 to $1.7150 . The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
November 22, 2024 Filed Nov 27, 2024 02:54 UTC	Beyond Air, Inc. XAIR · Entity 8379	GrantStock Options (Right to buy) · Derivative	25,000	Not disclosed Strike: $0.54	Not disclosed	Disclosure SEC source: 0001493152-24-047885 · ownership.xml · derivative · entry 14 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed F1 · kind: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F1 · price: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
November 22, 2024 Filed Nov 27, 2024 02:54 UTC	Beyond Air, Inc. XAIR · Entity 8379	Disposition to issuerStock Options (Right to buy) · Derivative	25,000	Not disclosed Strike: $4.25	Not disclosed	Disclosure SEC source: 0001493152-24-047885 · ownership.xml · derivative · entry 13 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed F1 · kind: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F1 · price: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
November 22, 2024 Filed Nov 27, 2024 02:54 UTC	Beyond Air, Inc. XAIR · Entity 8379	GrantStock Options (Right to buy) · Derivative	20,000	Not disclosed Strike: $0.54	Not disclosed	Disclosure SEC source: 0001493152-24-047885 · ownership.xml · derivative · entry 12 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · kind: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F1 · price: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
November 22, 2024 Filed Nov 27, 2024 02:54 UTC	Beyond Air, Inc. XAIR · Entity 8379	Disposition to issuerStock Options (Right to buy) · Derivative	20,000	Not disclosed Strike: $4.80	Not disclosed	Disclosure SEC source: 0001493152-24-047885 · ownership.xml · derivative · entry 11 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · kind: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F1 · price: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
November 22, 2024 Filed Nov 27, 2024 02:54 UTC	Beyond Air, Inc. XAIR · Entity 8379	GrantStock Options (Right to buy) · Derivative	25,000	Not disclosed Strike: $0.54	Not disclosed	Disclosure SEC source: 0001493152-24-047885 · ownership.xml · derivative · entry 10 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed F1 · kind: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F1 · price: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
November 22, 2024 Filed Nov 27, 2024 02:54 UTC	Beyond Air, Inc. XAIR · Entity 8379	Disposition to issuerStock Options (Right to buy) · Derivative	25,000	Not disclosed Strike: $5.32	Not disclosed	Disclosure SEC source: 0001493152-24-047885 · ownership.xml · derivative · entry 9 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed F1 · kind: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F1 · price: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
November 22, 2024 Filed Nov 27, 2024 02:54 UTC	Beyond Air, Inc. XAIR · Entity 8379	GrantStock Options (Right to buy) · Derivative	25,000	Not disclosed Strike: $0.54	Not disclosed	Disclosure SEC source: 0001493152-24-047885 · ownership.xml · derivative · entry 8 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed F1 · kind: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F1 · price: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
November 22, 2024 Filed Nov 27, 2024 02:54 UTC	Beyond Air, Inc. XAIR · Entity 8379	Disposition to issuerStock Options (Right to buy) · Derivative	25,000	Not disclosed Strike: $5.45	Not disclosed	Disclosure SEC source: 0001493152-24-047885 · ownership.xml · derivative · entry 7 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed F1 · kind: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F1 · price: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
November 22, 2024 Filed Nov 27, 2024 02:54 UTC	Beyond Air, Inc. XAIR · Entity 8379	GrantStock Options (Right to buy) · Derivative	30,000	Not disclosed Strike: $0.54	Not disclosed	Disclosure SEC source: 0001493152-24-047885 · ownership.xml · derivative · entry 6 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires not disclosed F1 · kind: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F1 · price: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
November 22, 2024 Filed Nov 27, 2024 02:54 UTC	Beyond Air, Inc. XAIR · Entity 8379	Disposition to issuerStock Options (Right to buy) · Derivative	30,000	Not disclosed Strike: $6.87	Not disclosed	Disclosure SEC source: 0001493152-24-047885 · ownership.xml · derivative · entry 5 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires not disclosed F1 · kind: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F1 · price: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
November 22, 2024 Filed Nov 27, 2024 02:54 UTC	Beyond Air, Inc. XAIR · Entity 8379	GrantStock Options (Right to buy) · Derivative	40,000	Not disclosed Strike: $0.54	Not disclosed	Disclosure SEC source: 0001493152-24-047885 · ownership.xml · derivative · entry 4 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires not disclosed F1 · kind: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F1 · price: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
November 22, 2024 Filed Nov 27, 2024 02:54 UTC	Beyond Air, Inc. XAIR · Entity 8379	Disposition to issuerStock Options (Right to buy) · Derivative	40,000	Not disclosed Strike: $6.28	Not disclosed	Disclosure SEC source: 0001493152-24-047885 · ownership.xml · derivative · entry 3 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires not disclosed F1 · kind: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F1 · price: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
November 22, 2024 Filed Nov 27, 2024 02:54 UTC	Beyond Air, Inc. XAIR · Entity 8379	GrantStock Options (Right to buy) · Derivative	45,000	Not disclosed Strike: $0.54	Not disclosed	Disclosure SEC source: 0001493152-24-047885 · ownership.xml · derivative · entry 2 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires not disclosed F1 · kind: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F1 · price: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
November 22, 2024 Filed Nov 27, 2024 02:54 UTC	Beyond Air, Inc. XAIR · Entity 8379	Disposition to issuerStock Options (Right to buy) · Derivative	45,000	Not disclosed Strike: $1.53	Not disclosed	Disclosure SEC source: 0001493152-24-047885 · ownership.xml · derivative · entry 1 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,000 shares Expires not disclosed F1 · kind: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F1 · price: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "\|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
August 14, 2024 Filed Aug 15, 2024 21:09 UTC	Beyond Air, Inc. XAIR · Entity 8379	PurchaseCommon Stock	39,266	$0.40	$15,565.04	Disclosure SEC source: 0001493152-24-032675 · ownership.xml · nonDerivative · entry 1 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,608 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.3827 to $0.3925, inclusive. The reporting person undertakes to provide to Beyond Air, Inc., any security holder of Beyond Air, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document
July 15, 2024 Filed Jul 17, 2024 20:30 UTC	SAB Biotherapeutics, Inc. SABS · Entity 5816	GrantStock Option (right to buy) · Derivative	20,000	$0.00 Strike: $2.90	$0.00	Disclosure SEC source: 0000950170-24-084291 · ownership.xml · derivative · entry 1 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2034-07-15 F1 · security: Represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on July 15, 2025, and 2026. F2 · security: This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended. F1 · derivative.exercise_date: Represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on July 15, 2025, and 2026. Read SEC document
May 20, 2024 Filed May 22, 2024 20:30 UTC	Editas Medicine, Inc. EDIT · Entity 5502	SaleCommon Stock	22,337	$5.61	$125,404.39	Disclosure SEC source: 0001650664-24-000044 · wk-form4_1716409797.xml · nonDerivative · entry 1 Lucera Erick · CIK 0001697616 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,829 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on May 12, 2023, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on May 17, 2024. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document
March 20, 2024 Filed Mar 22, 2024 01:01 UTC	Beyond Air, Inc. XAIR · Entity 8379	GrantStock Option (right to buy) · Derivative	45,000	$0.00 Strike: $1.53	$0.00	Disclosure SEC source: 0001493152-24-010865 · ownership.xml · derivative · entry 1 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2034-03-20 F1 · derivative.exercise_date: The option will vest as to 25% of the shares of common stock underlying the option on December 31, 2024, with the remainder vesting in equal annual installments on December 31 of each of the three ensuing years thereafter until vested in full. Read SEC document
March 02, 2024 Filed Mar 6, 2024 01:06 UTC	Editas Medicine, Inc. EDIT · Entity 5502	GrantStock Option (right to buy) · Derivative	106,000	$0.00 Strike: $10.53	$0.00	Disclosure SEC source: 0001650664-24-000019 · wk-form4_1709687193.xml · derivative · entry 3 Lucera Erick · CIK 0001697616 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,000 Underlying: Common Stock · 106,000 shares Expires 2034-03-01 F3 · derivative.exercise_date: This option was granted on March 2, 2024 and is scheduled to vest over four years in equal monthly installments beginning on April 2, 2024 through March 2, 2028. Read SEC document
March 02, 2024 Filed Mar 6, 2024 01:06 UTC	Editas Medicine, Inc. EDIT · Entity 5502	GrantCommon Stock	25,966	$0.00	$0.00	Disclosure SEC source: 0001650664-24-000019 · wk-form4_1709687193.xml · nonDerivative · entry 2 Lucera Erick · CIK 0001697616 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,166 F2 · kind: Reflects the acquisition, upon the achievement of a specified business development milestone, of a portion of a performance-based restricted stock unit award originally granted on May 17, 2023. The shares subject to the restricted stock unit award remain subject to time-based vesting conditions and will vest on May 17, 2024, subject to continued service. Read SEC document
March 02, 2024 Filed Mar 6, 2024 01:06 UTC	Editas Medicine, Inc. EDIT · Entity 5502	GrantCommon Stock	35,300	$0.00	$0.00	Disclosure SEC source: 0001650664-24-000019 · wk-form4_1709687193.xml · nonDerivative · entry 1 Lucera Erick · CIK 0001697616 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,200 F1 · kind: The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on March 2, 2025 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through March 2, 2028. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.